Literature DB >> 17922472

PAI-1 activity, but not fibrinogen or von Willebrand factor, is inversely related to LDL particle size in type 2 diabetes.

Ilse Mertens1, Isabelle Lemieux, An Verrijken, Jean-Pierre Després, Luc F Van Gaal.   

Abstract

BACKGROUND: Levels of fibrinogen, von Willebrand factor (vWF) and plasminogen activator inhibitor-1 (PAI-1) have been associated with small low-density lipoprotein (LDL) particles. However, it is not clear whether these associations are independent of visceral adiposity or other components of the metabolic syndrome such as triglycerides or insulin resistance.
METHODS: Visceral adipose tissue (VAT; CT-scan), fibrinogen, von Willebrand factor antigen (vWF:Ag), PAI-1 activity and different metabolic parameters such as total cholesterol (chol), HDL-chol, triglycerides, insulin resistance (homeostasis model assessment; HOMA-IR) were determined in 41 women and 78 men with type 2 diabetes. LDL particle size was assessed by polyacrylamide gradient gel electrophoresis.
RESULTS: PAI-1 activity was inversely related to LDL particle size after adjustment for age and body mass index (BMI) (r=-0.28; p=0.006) or age and VAT (r=-0.26; p=0.01), but not after adjustment for age and HOMA-IR (r=-0.15; p=0.148) or age and triglycerides (r=-0.04; p=0.679). In multiple regression analysis, LDL particle size did not independently determine PAI-1 activity levels. Fibrinogen and vWF:Ag did not seem to be related to LDL size.
CONCLUSIONS: PAI-1 activity levels, in contrast to fibrinogen and vWF:Ag, seem to be related to the small LDL phenotype in patients with type 2 diabetes. However, this relationship was not independent of insulin resistance or triglycerides. Copyright (c) 2007 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17922472     DOI: 10.1002/dmrr.779

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN: 1520-7552            Impact factor:   4.876


  6 in total

1.  Prothrombotic markers in asymptomatic dyslipidemic subjects.

Authors:  David Karasek; Helena Vaverkova; Milan Halenka; Dagmar Jackuliakova; Zdenek Frysak; Ludek Slavik; Dalibor Novotny
Journal:  J Thromb Thrombolysis       Date:  2011-01       Impact factor: 2.300

2.  Contribution of genetic and metabolic syndrome to omental adipose tissue PAI-1 gene mRNA and plasma levels in obesity.

Authors:  Luigi Bouchard; Marie-Claude Vohl; Stéfane Lebel; Frédéric-Simon Hould; Picard Marceau; Jean Bergeron; Louis Pérusse; Pascale Mauriège
Journal:  Obes Surg       Date:  2010-02-02       Impact factor: 4.129

3.  Simvastatin reduces circulating plasminogen activator inhibitor 1 activity in volunteers with the metabolic syndrome.

Authors:  Long Wang; Jason Rockwood; Danielle Zak; Sridevi Devaraj; Ishwarlal Jialal
Journal:  Metab Syndr Relat Disord       Date:  2008-06       Impact factor: 1.894

4.  Altered Daytime Fluctuation Pattern of Plasminogen Activator Inhibitor 1 in Type 2 Diabetes Patients with Coronary Artery Disease: A Strong Association with Persistently Elevated Plasma Insulin, Increased Insulin Resistance, and Abdominal Obesity.

Authors:  Katarina Lalić; Aleksandra Jotić; Nataša Rajković; Sandra Singh; Ljubica Stošić; Ljiljana Popović; Ljiljana Lukić; Tanja Miličić; Jelena P Seferović; Marija Maćešić; Jelena Stanarčić; Milorad Čivčić; Iva Kadić; Nebojša M Lalić
Journal:  Int J Endocrinol       Date:  2015-05-18       Impact factor: 3.257

5.  Influence of fibrinogen and C-RP on progression of peripheral arterial disease in type 2 diabetes: a preliminary report.

Authors:  Marijan Bosevski; Golubinka Bosevska; Lily Stojanovska
Journal:  Cardiovasc Diabetol       Date:  2013-02-01       Impact factor: 9.951

6.  Relationship of abdominal visceral and subcutaneous adipose tissue with lipoprotein particle number and size in type 2 diabetes.

Authors:  Susan Sam; Steven Haffner; Michael H Davidson; Ralph B D'Agostino; Steven Feinstein; George Kondos; Alfonso Perez; Theodore Mazzone
Journal:  Diabetes       Date:  2008-05-09       Impact factor: 9.461

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.